(S)-CR8 manufacturers
- (S)-CR8
-
- $353.00 / 2mg
-
2026-04-21
- CAS:1084893-56-0
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | (S)-CR8 Basic information |
| Product Name: | (S)-CR8 | | Synonyms: | CR8, (S)-Isomer - CAS 1084893-56-0 - Calbiochem;1-Butanol, 2-[[9-(1-methylethyl)-6-[[[4-(2-pyridinyl)phenyl]methyl]amino]-9H-purin-2-yl]amino]-, (2S)-;CR8, (S)-Isomer;(S)-CR8, CDK 1, 2, 5, 7 and 9 inhibitor;(S)-2-((9-Isopropyl-6-((4-(pyridin-2-yl)benzyl)amino)-9H-purin-2-yl)amino)butan-1-ol;N1-(Pyridin-4-ylmethyl)but-2-ene-1,4-diamine | | CAS: | 1084893-56-0 | | MF: | C24H29N7O | | MW: | 431.53 | | EINECS: | | | Product Categories: | | | Mol File: | 1084893-56-0.mol |  |
| | (S)-CR8 Chemical Properties |
| Boiling point | 671.4±65.0 °C(Predicted) | | density | 1.27±0.1 g/cm3(Predicted) | | storage temp. | +2C to +8C | | solubility | DMSO: soluble,Ethanol: soluble | | form | Off-white solid | | pka | 14.56±0.10(Predicted) | | color | White to off-white |
| | (S)-CR8 Usage And Synthesis |
| Description | (S)-CR8 is a second generation derivative of (R)-roscovitine and an inhibitor of cyclin-dependent kinase 1 (Cdk1/cyclin B), Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p25, and Cdk9/cyclin T (IC50s = 0.15, 0.08, 0.06, 0.12, and 0.11 μM, respectively). It also inhibits casein kinase CK1δ/ε (CKδ/ε) and DYRK1A (IC50s = 0.61 and 0.9 μM, respectively). (S)-CR8 reduces cell viability in human neuroblastoma cell lines, including SH-SY5Y, SK-N-AS, SK-N-BE, and IMR32 cells (IC50s = 0.43, 1.46, 0.13, and 0.14 μM, respectively). It also reduces protein levels of the survival factor Mcl-1 in SH-SY5Y cells. | | Uses | (S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective CDK inhibitor with IC50s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC50 0.40μM)[1]. | | Definition | ChEBI: (2S)-2-[[9-propan-2-yl-6-[[4-(2-pyridinyl)phenyl]methylamino]-2-purinyl]amino]-1-butanol is a phenylpyridine. | | References | [1] K Bettayeb, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008 Oct 2;27(44):5797-807. DOI:10.1038/onc.2008.191 |
| | (S)-CR8 Preparation Products And Raw materials |
|